Sales & Marketing News | pharmaphorum

News

Interchangeable high-concentration Humira approved in US

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat

News

CSL, Travere close on EU approval of IgAN drug sparsentan

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EM

News

Bavarian Nordic gets swift EU review of chikungunya shot

Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.

News

FDA will decide in June on Dupixent for COPD

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new

News

After Roche’s exit, Blueprint passes Gavreto on to Rigel

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug

News

United sues FDA to try to block rival’s drug application

In an unusual move, United Therapeutics has filed a lawsuit against the FDA that claims the regulator is sidestepping established norms in allowing rival Liquidia to file

Interchangeable high-concentration Humira approved in US

CSL, Travere close on EU approval of IgAN drug sparsentan

Bavarian Nordic gets swift EU review of chikungunya shot

FDA will decide in June on Dupixent for COPD

After Roche’s exit, Blueprint passes Gavreto on to Rigel

United sues FDA to try to block rival’s drug application

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks